跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

A1276

Sigma-Aldrich

Amastatin hydrochloride hydrate

powder, ≥97% (HPLC)

别名:

(2S,3R)-3-Amino-2-hydroxy-5-methylhexanoyl-Val-Val-Asp hydrochloride hydrate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H38N4O8 · HCl · xH2O
CAS号:
100938-10-1
分子量:
511.01 (anhydrous basis)
Beilstein:
8888370
MDL编号:
MFCD00150636
UNSPSC代码:
12352202
PubChem化学物质编号:
24890521
NACRES:
NA.77

产品名称

Amastatin hydrochloride hydrate, ≥97% (HPLC)

生物来源

synthetic (organic)

质量水平

200

方案

≥97% (HPLC)

表单

powder

mp

202-205 °C

溶解性

methanol: 1 mM (Stock solution stable for 1 month at −20 °C. Working solution stable for 1 day.)

抗生素抗菌谱

neoplastics

作用机制

enzyme | inhibits

储存温度

−20°C

SMILES字符串

Cl[H].[H]O[H].CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C21H38N4O8.ClH.H2O/c1-9(2)7-12(22)17(28)20(31)25-16(11(5)6)19(30)24-15(10(3)4)18(29)23-13(21(32)33)8-14(26)27;;/h9-13,15-17,28H,7-8,22H2,1-6H3,(H,23,29)(H,24,30)(H,25,31)(H,26,27)(H,32,33);1H;1H2/t12-,13+,15+,16+,17+;;/m1../s1

InChI key

WBYDQJQQTMJMQH-AFROIDPFSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Chemical structure: peptide

生化/生理作用

It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts angiotensin II to angiotensin III. Potentiates the CNS effects of vasopressin and oxytocin in vivo.

Effective concentration: 1-10 μM.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
SLCR0103
SLCR2178
SLCL9653
SLCJ4460
SLCB3369

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Zollner, H.
Handbook of Enzyme Inhibitors, 2nd Ed., 547-547 (1993)
Beynon, R.J. and Bond, J.S.
Proteolytic Enzymes: A Practical Approach, 247-247 (1989)
Yu Wang et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21419-e21419 (2021-02-11)
In the early phase of the Coronavirus disease 2019 (COVID-19) pandemic, it was postulated that the renin-angiotensin-system inhibitors (RASi) increase the infection risk. This was primarily based on numerous reports, which stated that the RASi could increase the organ Angiotensin-converting

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门